Eli Lilly Announces Foundayo Is Now Available To Adults With Obesity Or Overweight With Weight-Related Medical Problems Following FDA Approval On April 1

Foundayo is now available via LillyDirect® and telehealth providers and is shipping to retail pharmacies nationwide

Foundayo, the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, starts at $25 per month with commercial coverage and $149 per month with self-pay

INDIANAPOLIS, April 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that Foundayo™ (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems following the U.S. Food and Drug Administration (FDA) approval on April 1, 2026. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo is a once-daily pill for weight loss that can be taken without food or water restrictions. People can now access Foundayo via LillyDirect® and telehealth providers, with availability expanding to U.S. retail pharmacies beginning today.